News | May 28, 2026
Gandhar Oil posts robust FY26 profit
PAT soars 201%, EBITDA up 88% on strong PHPO demand & margin expansion
PAT soars 201%, EBITDA up 88% on strong PHPO demand & margin expansion
For the full year, standalone gross revenue crossed Rs. 1,700 crore
Revenue from operations climbed 13% to Rs. 886.87 crore
Eris Lifesciences posts sharp profit surge in FY26 driven by strong diabetes portfolio growth
The company’s revenue stood at Rs. 287.68 crore, reflecting a 4.7 percent increase over Rs. 274.71 crore reported in FY25
Profit after tax took a sharp hit, falling to Rs. 33 Cr in Q4 FY26, down from Rs. 106 Cr in Q4 FY25 and Rs. 52 Cr in Q3 FY26
US formulations grew 11% to Rs. 564 crore as Alembic enters US branded pharmaceuticals market with launch of Pivya
FY26 revenue rises to Rs. 4,359 crore as India’s leading CDMO strengthens global footprint with EU GMP certifications, UK MHRA approval and Europe supplies
Backed by Semaglutide launches, the company reported 47% quarter-on-quarter revenue growth in Q4 FY26, with EBITDA expanding more than fivefold
Global specialty pipeline accelerates growth
Subscribe To Our Newsletter & Stay Updated
